Rimonabant: Just an antiobesity drug? Current evidence on its pleiotropic effects

Molecular Pharmacology

Volumn 71, Issue 6, 2007, Pages 1445-1456

  Bifulco, Maurizio ^a   Grimaldi, Claudia ^a   Gazzerro, Patrizia ^a   Pisanti, Simona ^a   Santoro, Antonietta ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANTIOBESITY AGENT; BROMOPRAVADOLINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; IODOPRAVADOLINE; PLACEBO; RIMONABANT; UNCLASSIFIED DRUG; WIN 56098;

ALCOHOLISM; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CALORIC INTAKE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEPRESSION; DIARRHEA; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSLIPIDEMIA; FERTILIZATION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GLIOMA; HEROIN DEPENDENCE; HUMAN; HUNGER; HYPERACTIVITY; INFERTILITY; LIVER FIBROSIS; MANTLE CELL LYMPHOMA; METABOLIC SYNDROME X; MOOD DISORDER; NAUSEA; NEUROTOXICITY; NONHUMAN; OBESITY; OPIATE ADDICTION; PARKINSON DISEASE; PENIS ERECTION; PLEIOTROPY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RISK FACTOR; SHORT SURVEY; SINGLE DRUG DOSE; SMOKING CESSATION; THYROID CANCER; ULCER; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; HUMANS; NEURODEGENERATIVE DISEASES; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SMOKING CESSATION; SUBSTANCE-RELATED DISORDERS;

EID: 34347336599     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.033118     Document Type: Short Survey

References (119)

1. Abood ME, Rizvi G, Sallapudi N, McAllister S (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309:197-201.
2. Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, and Yamamoto T (2004) Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 29:1470-1478.
3. Anthenelli RM and Déspres JP (2004) Effect of Rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). American College of Cardiology 53rd Annual Scientific Session; 2004 Mar 7-10; New Orleans, LA.
4. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrié P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Pychopharmacology 132:104-106.
5. Barrero FJ, Ampuero I, Morales B, Vives F, de Dios Luna Del Castillo J, Hoenicka J, Garcia Yebenes J (2005) Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 5:135-141.
6. 1 receptors mediate the vasodilated state in advanced cirrhosis. Nat Med 7:827-832.
7. Bátkai S, Pacher P, Járai Z, Wagner JA, and Kunos G (2004) Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol 287:H595-H600.
8. Beardsley PM and Thomas BF (2005) Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav Pharmacol 16:275-296.
9. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in Adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914.
10. Bernard C, Milh M, Morozov YM, Ben-Ari Y, Freund TF, and Gozlan H (2005) Altering cannabinoid signaling during development disrupts neuronal activity. Prot Natl Acad Sci USA 102:9388-9393.
11. Bifulco M, Di Marzo V (2002) Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8:547-550.
12. Bifulco M, Gazzerro P, Laezza C, and Pentimalli F (2007) Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion. Oncol Rep 17:813-816.
13. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V (2001) Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15:2745-2747.
14. Bifulco M, Laezza C, Pisanti S, and Gazzerro P (2006) Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148:123-135.
15. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, DI Marzo V (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18:1606-1608.
16. Bost F, Aouadi M, Caron L, Even P, Belmonte N, Prot M, Dani C, Hofman P, Pages G, Pouyssegur J, et al. (2005) The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 54:402-411.
17. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
18. Braida D and Sala M (2000) Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats. Neuroreport 11:2025-2029.
19. Chehab FF (2000) Leptin as a regulator of adipose mass and reproduction. Trends Pharmacol Sci 21:309-313.
20. Centonze D, Rossi S, Prosperetti C, Tscherter A, Bernardi G, Maccarrone M, and Calabresi P (2005) Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry 57:1583-1589.
21. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M, Bermudez-Silva FJ, Navarro M, Ciccocioppo R, et al. (2005) Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci 21:2243-2251.
22. 1) receptor antagonist, rimonabant(SR141716). Neuropsychopharmacology 30:145-155.
23. 1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451-463.
24. Colombo G, Agabio R, Fa M, Guano L, Lobina C, Loche A, Reali R, and Gessa GL (1998) Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol 33:126-130.
25. Compton DR, Aceto MD, Lowe J, and Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of Astetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
26. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Investig 112:423-431.
27. Croci T, Landi M, Galzin AM, and Marini P (2003) Role of cannabinoid CB1 receptors and tumor necrosis factor-a in the gut and systemic anti-inflammatory activity of SR141716 (Rimonabant) in rodents. Br J Pharmacol 140:115-122.
28. da Silva GE, Fernandes MS, and Takahashi RN (2003) Potentiation of penile erection and yawning responses to apomorphine by cannabinoi receptorantagonist in rats. Neurosci Lett 349:49-52.
29. Dennedy MC, Friel AM, Houlihan DD, Broderick VM, Smith T, and Morrison JJ (2004) Cannabinoids and the human uterus during pregnancy. Am J Obstet Gynecol 190:2-9.
30. De Petrocellis L, Cascio MG, Di Marzo V (2004) The cannabinoid system: a general view and la test additions. Br J Pharmacol 141:765-774.
31. Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Segui M, and Casellas P (1998) The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 425:419-425.
32. Déspres JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134.
33. De Vries TJ, De Vries W, Janssen MC, and Schoffelmeer AN (2005) Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav Brain Res 161:164-168
34. De Vries TJ, Homberg JR, Binnekade R, Raaso H, and Schoffelmeer AN (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 168:164-169.
35. De Vries TJ and Schoffelmeer AN (2005) Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26:420-426.
36. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Shuurman K, Dieben J, Vanderschuren LJ, and Schoffelmeer AN (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151-1154. .
37. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 9:771-783.
38. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (Lond) 410:822-825.
39. Duarte C, Alonso R, Bichet N, Cohen C, Soubrié P, and Thiébot ME (2004) Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR14161716), of the potentiation by quinelorane of food primed reinstatement of food-seeking behaviour. Neuropsychopharmacology 29:911-920.
40. Economidou D, Mattioli l, Cifani C, Perfumi M, Massi M, Cuomo V, Trabace L, and Ciccocioppo R (2006) Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology 183:394-403.
41. Fagerstrom K, and Balfour DJ (2006) Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs 15:107-116.
42. Fattore L, Spano S, Cossu G, Deiana S, Fadda P, and Fratta W (2005) Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 48:1097-1104.
43. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CBi and CB2 receptors. Mol Pharmacol 48:443-450.
44. Fernandez-Ruiz J and Gonzales S (2005) Cannabinoid control of motor function at the basal ganglia. Handb Exp Pharmacol (168):479-507.
45. Flygare J, Gustafsson K, Kimby E, Christensson B, and Sander B (2005) Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 579:6885-6889.
46. Freund TF, Katona I, and Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066.
47. Gable DR, Hurel SJ, and Humphries SE (2006) Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 188:231-244.
48. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, and Bensaid M (2006) The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69:471-478.
49. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C, Bifulco M (2007) Association between Cannabinoid type-1 receptor polymorphism and body mass index in a Southern Italian population. Int J Obes, in press.
50. Gifford AN and Ashby CR (1996) Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther 277:1431-1436.
51. Giuffrida A, Parsone LH, Kerr TM, de Fonseca FR, Navarro M, and Pomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosi 2:358-363.
52. Grimaldi C, Pisanti C, Laezza C, Malfitano AM, Santoro A, Vitale M, Caruso M, Notarnicola M, Iacuzzo I, Portella G, et al. (2006) Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312:363-373.
53. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, and Sellers TA (2005) Association of Gain and Loss of Weight before and after Menopause with Risk of Postmenopausal Breast Cancer in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 14:656-661.
54. Hilairet S, Bouaboula M, Carrière D, Le Fur G, and Casellas P (2003) Hypersensitization of the orexin 1 receptor by the CB1 receptor. J Biol Chem 278:23731-23737.
55. Herkenham M, Lynn AB, de Costa BR, and Richfield EK (1991a) Neuronal localization of cannabinoid receptors in basal ganglia of the rat. Brain Res 547:267-274.
56. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1991b) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
57. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
58. Hou Y, Yang J, Zhao G, and Yuan Y (2004) Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway. J Cell Biochem 93:1203-1209.
59. Hube F and Hauner H (1999) The role of TNFalfa in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Hormone Metab Res 31:626-631.
60. Jacobsson SO, Wallin T, and Fowler CJ (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299:951-959.
61. Jansen EM, Haycock DA, Ward SJ, and Seybold VS (1992) Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res 575:93-102.
62. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, and Friedman H (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486-496.
63. Landsman RS, Burkey TH, Consroe P, Roeske WR, and Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1-R2.
64. Lange JHM and Kruse CG (2005) Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov Today 10:693-702.
65. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, and Fernandez-Ruiz J (2003) Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 14:813-816.
66. Liu WM, Duan EK, and Cao YJ (2002) Effect of anandamide on embryo implantation in the mouse. Life Sci 71:1623-1632.
67. Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agrò A (2000a) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275:31938-31945.
68. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agrò A (2000b) Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 355:1326-1329.
69. Maccarrone M, Finazzi-Agrò A (2004) Anandamide hydrolase: a guardian angel of human reproduction? Trends Pharmacol Sci 25:353-357.
70. Maldonado R, Valverde O, and Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225-232.
71. Mallat A and Lotersztajn S (2006) Endocannabinoids as novel mediators of liver diseases. J Endocrinol Investig 29:58-65.
72. Mallet PE and Beninger RJ (1998) The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9- tetrahydrocannabinol or anandamide. Psychopharmacology 140:11-19.
73. Manabe Y, Toda S, Miyazaki K, and Sugihara H (2003) Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol 201:221-228.
74. Mazzola C, Micale V, and Drago F (2003) Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol 477:219-225.
75. Mechoulam R, Fride E, Di marzo V (1998) Endocannabinoids. Eur J Pharmacol 359:1-18.
76. Melis MR, Succu S, Mascia MS, Sanna F, Melis T, Castelli MP, and Argiolas A (2006) The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide. Neuropharmacology 50:219-228.
77. 9 tetrahydrocannabinol in rats. Jpn J Pharmacol 87:297-308.
78. 1 receptors in spinal pain pathways in rat. Eur J Pharmacol 514:159-164.
79. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, et al. (2001) Interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 15:5344-5350.
80. Nesto RW (2005) Managing cardiovascular risk in patients with metabolic syndrome. Clin Cornerstone 7:46-51.
81. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Investig 115:1298- 1305.
82. Perio A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, and Soubrie P (1996) Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR141716A. Behav Pharmacol 7:65-71.
83. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
84. Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (London) 1:S13-S18.
85. Pertwee RG, Fernando SR, Nash JE, and Coutts AA (1996) Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 118:2199-2205.
86. 3H]SR141716A. Neuroreport 7:789-792.
87. Pi-Sunyer XF, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group (2006) Effect of Rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: a randomized controlled trial. J Am Med Assoc 295:761-775.
88. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, and Bifulco M (2003) Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17:1771-1773.
89. Powles T, Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T, and Liu WM (2005) Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105:1214-1221.
90. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, and Soubrié P (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol 284:R345- R353.
91. Rinaldi-Carmona M, Barth F, Healume M, Shire D, Calandra B, Congy C, Martinez S Maruani J, Neliat G, Caput D, Ferrara P, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
92. Robson P (2005) Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 168:719-756.
93. 1, the activation of which inhibits motilità, acrosome reaction, and mitochondrial function. J Clin Endocrinol Metab 90: 984:991.
94. Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramon y Cajal S, and Guzman M (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61:5784-5789.
95. Sarfaraz S, Afaq F, Adhami VM, and Mukhtar H (2005) Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65:1635-1641.
96. Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C, and Bifulco M (2006) The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 70:1298-1306.
97. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368:1660-1672.
98. Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, Pomelli D, and Giuffrida A (2002) N-Acylethanomines in human reproductive fluids. Chem Phys Lipids 121:211-227.
99. Segovia G, Mora F, Crossman AR, and Brotchie JM (2003) Effects of CB1 cannabinoid receptor modulating compounds on the hiperkinesia induced by high-dose Levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord 18:138-149.
100. Shire D, Calandra B, Delpech M, Dumont X, Kagha M, Le Fur G, Caput D, Ferrara P. (1996) Structural features of the central cannabinoid CB, receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem 271:69414946.
101. Solbrig MV, Adrian R, Baratta J, Piomelli D, and Giuffrida A (2005) A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. Exp Neurol 194:355-362.
102. Spanagel R, Weiss F (1999) The dopamine hypothesis of reward: past and current status. Trends Neurosci 22:521-527.
103. Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, and Fratta W (2004) CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol 143:343-350.
104. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Buhrer C, et al. (2005) NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 102:15605-15610.
105. Succu S, Mascia MS, Sanna F, Melis T, Argiolas A, and Melis MR (2006) The cannabinoid CB1 receptor antagonist SR141716 induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats. Behav Brain Res 169:274-281.
106. Szabo B, Dörner L, Pfreundtner C, Nörenberg W, and Starke K (1998) Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85:395-403.
107. Takahashi RN, Pampona FA, and Fernandes MS (2005) The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 380:270-275.
108. Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science (Wash DC) 276:2048-2050.
109. Terranova JP, Storme JJ, Lafon N, Perio A, Rinaldi-Carmona M, Le Fur G, and Soubrié P (1996) Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 126:165-172.
110. 3H]11-OH delta 9-THC-DMH. J Pharmacol Exp Ther 263:1383-1390.
111. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, Serriere-Lanneau V, Ledent C, Mallat A, and Lotersztajn S (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12:671-676.
112. Valverde O, Karsak M, and Zimmer A (2005) Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 168:117-145.
113. Van Gaal LF, Rissanen AM, Scheen A, Ziegler O, Rössner S, RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397.
114. Varga K, Wagner JA, Bridgen DT, and Kunos G (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12:1035-1044.
115. Walker JM, Hohmann AG (2005) Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 168:509-554.
116. Wang L, Liu J, Harvey-White J, Zimmer A, and Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Prot Natl Acad Sci USA 100:1393-1398.
117. Wilson RI, Nicoll RA (2002) Endocannabinoids signaling in the brain. Science (Wash DC) 296:678-682.
118. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, and Chuang LM (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819.
119. Yoon S, and Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21-44.